“Solos is putting added emphasis on its MammoView line of breast endoscopy instrumentation by developing new instruments which will include a new biopsy device to complement its existing line and is in the process of obtaining the necessary regulatory approvals to broaden our markets,” said Bob Segersten, president of Solos Endoscopy, in the release.
The company intends to market MammoView and its components to hospitals across the country and internationally.
Solos Endoscopy instruments are FDA approved. The company expects to receive the CE mark for its entire instrument line and will then market MammoView within countries that recognize the CE mark.
Related Articles on Solos Endoscopy:
Solos Endoscopy Reports 16% Sales Increase
